Purpose
To optimize a circular RNA-based vaccine candidate against Respiratory Syncytial Virus that demonstrates superior neutralization and durable immune response in preclinical models, advancing affordable vaccine platforms for global use.
Grantee
Division
Africa & India Offices,
Global Health
Date
SEPTEMBER 2026
Region served
GLOBAL
Committed amount
$1,019,132
Grant topic
Global Health and Development Public Awareness and Analysis,
Vaccine Development
Duration (months)
18
Grantee location
Chennai, Tamil Nadu, India
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.